Quarterly report pursuant to Section 13 or 15(d)

Subsequent Event

v3.8.0.1
Subsequent Event
9 Months Ended
Sep. 30, 2017
Subsequent Events [Abstract]  
Subsequent Event
Subsequent Event

On October 1, 2017, the Company acquired 80% of a national, full-service specialty pharmacy, providing service to patients with certain chronic respiratory and digestive conditions. The purchase price consists of $53 million in cash paid at closing, $7 million in deferred consideration, and up to an additional $32 million of contingent consideration to be paid upon meeting certain performance metrics.